<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T04:17:03Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/120991" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/120991</identifier><datestamp>2025-12-05T09:33:52Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478799</setSpec><setSpec>col_2072_478916</setSpec><setSpec>col_2072_478917</setSpec><setSpec>col_2072_478929</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors</dc:title>
   <dc:creator>Juliachs Milà, Mercè</dc:creator>
   <dc:creator>Muñoz, C.</dc:creator>
   <dc:creator>Moutinho, Cátia</dc:creator>
   <dc:creator>Vidal-Bel, August</dc:creator>
   <dc:creator>Condom i Mundó, Enric</dc:creator>
   <dc:creator>Esteller, Manel</dc:creator>
   <dc:creator>Graupera i Garcia-Milà, Mariona</dc:creator>
   <dc:creator>Casanovas i Casanovas, Oriol</dc:creator>
   <dc:creator>Germà Lluch, José Ramón</dc:creator>
   <dc:creator>Villanueva Garatachea, Alberto</dc:creator>
   <dc:creator>Viñals Canals, Francesc</dc:creator>
   <dc:subject>Malalties del testicle</dc:subject>
   <dc:subject>Tumors</dc:subject>
   <dc:subject>Càncer</dc:subject>
   <dc:subject>Resistència als medicaments</dc:subject>
   <dc:subject>Medicaments antineoplàstics</dc:subject>
   <dc:subject>Cisplatí</dc:subject>
   <dc:subject>Testis diseases</dc:subject>
   <dc:subject>Tumors</dc:subject>
   <dc:subject>Cancer</dc:subject>
   <dc:subject>Drug resistance</dc:subject>
   <dc:subject>Antineoplastic agents</dc:subject>
   <dc:subject>Cisplatin</dc:subject>
   <dc:description>Purpose: we examined whether PI3K-AKT or extracellular signal-regulated kinase (ERK) signaling pathways could play a role in the development of cisplatin (CDDP) resistance in testicular germ cell tumor (TGT) cells. Experimental design: we compared AKT and ERK activation levels in CDDP-sensitive testicular tumor cells and in their corresponding CDDP-resistant-derived cells. We also analyzed these pathways in orthotopic testicular tumors and human patient samples. Results: our results indicated that there was overactivation of AKT in CDDP-resistant cells compared with sensitive cells, but no effect on activated ERK levels. We observed an increase in mRNA and protein levels for platelet-derived growth factor (PDGF) receptor β and PDGF-B ligand. These were responsible for AKT overactivation in CDDP-resistant cells. When PDGFRβ levels were decreased by short hairpin RNA (shRNA) treatment or its activation was blocked by pazopanib, CDDP-resistant cells behaved like sensitive cells. Moreover, CDDP-resistant cells were more sensitive to incubation with PDGFRβ inhibitors such as pazopanib or sunitinib than sensitive cells, a finding consistent with these cells being dependent on this signaling pathway. We also found overexpression of PDGFRβ and pAKT in CDDP-resistant choriocarcinoma orthotopic tumor versus their CDDP-sensitive counterparts. Finally, we found high PDGFRβ levels in human testicular tumors, and overexpression in CDDP-resistant testicular choriocarcinomas compared with the CDDP-sensitive and nontreated tumors. Conclusions: the PDGFRβ-AKT pathway plays a critical role in the development of CDDP resistance in testicular tumoral cells.</dc:description>
   <dc:date>2018-03-22T10:43:30Z</dc:date>
   <dc:date>2018-03-22T10:43:30Z</dc:date>
   <dc:date>2014-02</dc:date>
   <dc:date>2018-03-22T10:43:31Z</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
   <dc:identifier>1078-0432</dc:identifier>
   <dc:identifier>https://hdl.handle.net/2445/120991</dc:identifier>
   <dc:identifier>638378</dc:identifier>
   <dc:identifier>24277456</dc:identifier>
   <dc:identifier>26088228</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Versió postprint del document publicat a: https://doi.org/10.1158/1078-0432.CCR-13-1131</dc:relation>
   <dc:relation>Clinical Cancer Research, 2014, vol. 20, num. 3, p. 658-667</dc:relation>
   <dc:relation>https://doi.org/10.1158/1078-0432.CCR-13-1131</dc:relation>
   <dc:rights>(c) American Association for Cancer Research, 2014</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>10 p.</dc:format>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>American Association for Cancer Research</dc:publisher>
   <dc:source>Articles publicats en revistes (Ciències Fisiològiques)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>